Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity
BRAF V600E is the most frequent oncogenic protein kinase mutation known. Furthermore, inhibitors targeting “active” protein kinases have demonstrated significant utility in the ...